Healthcare Capital Partners... Net Worth

The estimated Net Worth of Healthcare Capital Partners... is at least $153 million dollars as of 15 June 2020. Healthcare Partners owns over 1,500,000 units of Constellation Pharmaceuticals Inc stock worth over $152,955,000 and over the last 5 years Healthcare sold CNST stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Healthcare Partners CNST stock SEC Form 4 insiders trading

Healthcare has made over 3 trades of the Constellation Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Healthcare bought 1,500,000 units of CNST stock worth $11,310,000 on 15 June 2020.

The largest trade Healthcare's ever made was buying 1,500,000 units of Constellation Pharmaceuticals Inc stock on 15 June 2020 worth over $11,310,000. On average, Healthcare trades about 800,909 units every 46 days since 2019. As of 15 June 2020 Healthcare still owns at least 4,500,000 units of Constellation Pharmaceuticals Inc stock.

You can see the complete history of Healthcare Partners stock trades at the bottom of the page.

Insiders trading at Constellation Pharmaceuticals Inc

Over the last 15 years, insiders at Constellation Pharmaceuticals Inc have traded over $36,293,867 worth of Constellation Pharmaceuticals Inc stock and bought 6,651,976 units worth $88,473,679 . The most active insiders traders include Peter Svennilson, Of The University Of Califo... et Anthony B Evnin. On average, Constellation Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $4,934,940. The most recent stock trade was executed by Mark A Goldsmith on 4 March 2021, trading 14,987 units of CNST stock currently worth $509,408.

What does Constellation Pharmaceuticals Inc do?

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor CPI-0610 for the treatment of myelofibrosis as well as the EZH2 inhibitor CPI-0209 for the treatment of solid tumors. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.

Complete history of Healthcare Partners stock trades at Altimmune Inc et Constellation Pharmaceuticals Inc

Constellation Pharmaceuticals Inc executives and stock owners

Constellation Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Jigar Raythatha,
  President, Chief Executive Officer, Director
• Emma Reeve,
  Chief Financial Officer, Senior Vice President, Treasurer
• Scott Braunstein,
  Independent Director
• Mark Goldsmith,
  Independent Chairman of the Board
• Robert Tepper,
  Independent Director
• James Audia,
  Director
• Elizabeth Trehu,
  Independent Director
• Steven Hoerter,
  Independent Director
• Ronald Aldridge,
  IR Contact Officer
• Richard Levy,
  Independent Director
• Jeffrey Humphrey,
  Chief Medical Officer
• Karen Valentine,
  Chief Legal Officer, General Counsel
• Patrick Trojer,
  Chief Scientific Officer
• Group L Pcolumn Group Gp, L...,
  
• Group L Pcolumn Group Iii, ...,
  
• Group L Pgoeddel David V Sv...,
  
• Group L Pcolumn Group Iii, ...,
  
• Rock Ventures Lp Third Rock...,
  
• Advisors Llc Orbi Med Globa...,
  
• Of The University Of Califo...,
  
• Capital, Llc Casdin Partner...,
  
• Peter Svennilson,
  Director
• Ventures Ii, Lp Spur Capita...,
  
• Fund L.P.Topspin Biotech Fu...,
  
• Berg Ltd Mountain,
  10% owner
• Anthony B Evnin,
  Director
• Group L Pcolumn Group Gp, L...,
  
• Onco Ltd Precision,
  10% owner
• Venture Investments, Llc Al...,
  10% owner
• James E Deerfield Mgmt L.P....,
  
• Jerry A Hatfield,
  Sr. Vice President, Operations
• Michael John Hoffman,
  President and CEO
• Daniel Ingram,
  Senior V.P., Sales/Marketing
• James Ct Bolton,
  Senior Vice President
• James A Lewis,
  Director
• Frank J Mechura,
  Director
• Angus Smith,
  Director
• Donald P Deubel,
  SVP, Corporate Technologies
• Christopher Phelan,
  VP European Operations
• Walter Stanley Sobon,
  Executive VP and CFO
• David J Waksman,
  Senior Vice President
• Michael Dudley Mc Daniel,
  Director
• John P Neafsey,
  Director
• A Alexander Ii Taylor,
  Director
• Group L Pcolumn Group Gp, L...,
  
• Healthcare Capital Partners...,
  
• Adrian Senderowicz,
  Chief Medical Officer